Evidence map›Paper›PMID 34930934›Full record

ArticleScientific reports2021

Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis.

Mineaki Kitamura, Kosei Yamaguchi, Yuki Ota, Satoko Notomi, Maya Komine, Rika Etoh, Takashi Harada, Satoshi Funakoshi, Hiroshi Mukae, Tomoya Nishino

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mineaki KitamuraDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. minekitamura@nagasaki-u.ac.jp.
Kosei YamaguchiDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yuki OtaDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Satoko NotomiNagasaki Renal Center, Nagasaki, Japan.
Maya KomineNagasaki Renal Center, Nagasaki, Japan.
Rika EtohNagasaki Renal Center, Nagasaki, Japan.
Takashi HaradaNagasaki Renal Center, Nagasaki, Japan.
Satoshi FunakoshiNagasaki Renal Center, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tomoya NishinoDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki Medical Center · JPNagasaki University · JPSasebo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although polypharmacy is common among patients on hemodialysis (HD), its association with prognosis remains unclear. This study aimed to elucidate the association between the number of prescribed medicines and all-cause mortality in patients on HD, accounting for essential medicines (i.e., antihypertensives, antidiabetic medicines, and statins) and non-essential medicines. We evaluated 339 patients who underwent maintenance HD at Nagasaki Renal Center between July 2011 and June 2012 and followed up until June 2021. After adjusting for patient characteristics, the number of regularly prescribed medicines (10.0 ± 4.0) was not correlated with prognosis (hazard ratio [HR]: 1.01, 95% confidence interval [CI] 0.97-1.05, p = 0.60). However, the number of non-essential medicines (7.9 ± 3.6) was correlated with prognosis (HR: 1.06, 95% CI 1.01-1.10, p = 0.009). Adjusting for patient characteristics, patients who were prescribed more than 10 non-essential medicines were found to have a significantly higher probability of mortality than those prescribed less than five non-essential medicines, with a relative risk of 2.01 (p = 0.004). In conclusion, polypharmacy of non-essential medicines increases the risk of all-cause mortality in patients on HD. As such, prescribing essential medicines should be prioritized, and the clinical relevance of each medicine should be reviewed by physicians and pharmacists.

Indexed as

Drugs, EssentialPolypharmacyAgedCardiovascular DiseasesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKaplan-Meier EstimateKidney Failure, ChronicMaleMiddle AgedPrescription DrugsPrognosisProportional Hazards ModelsRenal DialysisRetrospective StudiesDrugs, EssentialHydroxymethylglutaryl-CoA Reductase InhibitorsPrescription Drugs

Identifiers

PMID34930934
PMCPMC8688458
OpenAlexW4200442897

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.